Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs ACM Research Inc (ACMR) Price & Performance

Abeona Therapeutics IncTrade
ACM Research IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs ACM Research Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while ACM Research Inc trades at $81.38 (market cap $5.57B). The key difference: ACM Research Inc is far larger — about 13.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, ACM Research Inc nearer its low. Which is the better fit depends on your goals.

ABEOACMR
Market Cap
$421.19M$5.57B
Sector
HealthTechnology
52-Week High
$7.45$126.89
52-Week Low
$4.17$24.93
Enterprise Value
$276.10M$4.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.

Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.

ACM Research Inc

ACMR trades at $81.26, up 2.33% today, with a neutral technical signal and bearish moving averages. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $0.61 versus $0.42 expected, revenue growth of 36% year-over-year to $292.9 million, and raised 2026 guidance. Net income margin improved to 14.48% in 2026 from 10.43% in 2025, supported by robust orders and product expansion.

Outlook remains positive with an 80% analyst buy rating and consensus price target of $127.50, implying significant upside. Risks include high P/E of 37.7, negative operating cash flow, and semiconductor cycle volatility. Growth catalysts are new wet processing platforms and overseas expansion, but execution on guidance is critical.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About ACM Research Inc

ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.

Read more on ACMR